Poland’s Chief Pharmaceutical Inspector has ordered immediate nationwide withdrawal of asthma medication Veriflo due to quality concerns affecting thousands of patients.
Veriflo Withdrawal Details
The withdrawn product is Veriflo, Salmeterol + Fluticasone propionate, inhalation aerosol, suspension, in a dose of 25 micrograms + 50 micrograms/measured dose, packaging 120 doses. The product has permit number 26935, and the responsible entity is Zentiva k.s. with its seat in Prague.
Preparations containing salmeterol and fluticasone are part of the therapy standards in pulmonology. For many patients, it is a daily element of treatment.
Emergency Decision from Chief Inspector
The decision of the Chief Pharmaceutical Inspector dated March 2, 2026 concerns the withdrawal from the entire country of all batches of the specified medicinal product and the prohibition of its introduction to circulation.
The decision was given immediate enforceability, which in practice means it is effective from the moment of delivery – without waiting for its finalization.
Reasons for Withdrawal
From the justification, it appears that the National Medicines Institute found that the product does not meet the quality requirements specified in the registration documentation.
In practice, this means the risk that the patient may have received a dose of the drug different from the one approved in the documentation. And in the case of inhalation drugs, dose precision is crucial for therapy effectiveness and safety.
Patient Actions
If you have Veriflo at home in a dose of 25 µg + 50 µg/dose (120 doses), check the name and dose on the packaging. The decision concerns this specific product and all its batches.
Do not use the medication covered by the decision, but first contact your attending physician to determine alternative therapy. Then go to the pharmacy – the pharmacist should accept the product due to the withdrawal decision.
Refund and Alternatives
Pharmaceutical law provides that in the event of a product’s withdrawal from circulation, pharmacies accept returns from patients. Detailed rules are implemented by pharmacies based on the GIF decision and wholesale procedures.
Other preparations containing the combination of salmeterol and fluticasone in different doses are available on the market. The doctor may decide to switch to another equivalent product, adjust the dose, or temporarily modify the treatment regimen.
